AI Renews Prescriptions: Innovation or Public Health Crisis?

An artificial intelligence platform called Doctronic is currently renewing prescriptions for patients in Utah without direct physician involvement, operating under a state regulatory exemption. This commercial program, which costs users $4 per renewal, has raised significant concerns regarding patient safety. The entire scientific justification for its safety is based on a single preprint study posted in July, which has not undergone peer review and whose authors hold equity in the company. Concerns are mounting that AI development is outpacing necessary regulations, posing substantial risks to patient well-being.

Doctronic's operation relies on Utah's AI regulatory sandbox, a framework intended for testing innovations with reduced oversight. While the company claims its AI matches human clinician treatment plans 99.2 percent of the time, this figure was derived from urgent care encounters, not the chronic medication renewals central to the Utah pilot. This distinction is critical, as applying even a 99.2 percent accuracy rate at scale could lead to thousands of patient errors, with unknown systematic biases affecting vulnerable populations. Furthermore, research indicates AI systems can exhibit performance disparities across different patient demographics, a potential blind spot for Doctronic given the lack of data transparency.

Leading medical organizations, including the American College of Physicians and the American Medical Association, have voiced strong safety concerns, emphasizing that prescription renewals require physician involvement and that accuracy claims do not substitute for clinical judgment. The Food and Drug Administration (FDA) currently states the program falls outside its regulatory purview. Experts advocate for expanded FDA oversight, requiring independent validation before AI deployment in states with regulatory sandboxes, and mandating public availability of training data and validation results for AI medical decision systems. Addressing this regulatory void proactively is crucial before autonomous AI prescribing becomes widespread.